Erasca to Present at Upcoming Investor Conferences in November

Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) will participate in investor conferences in November 2023, including Jefferies London Healthcare Conference and 6th Annual Evercore ISI HealthCONx Conference. Webcasts and one-on-one investor meetings are planned. The company focuses on therapies for RAS/MAPK pathway-driven cancer.

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancer, today announced that management will participate in the following investor conferences in November 2023. Management will also participate in one-on-one investor meetings.

Jefferies London Healthcare Conference (November 14 – 16, 2023)
Location: Waldorf Hilton, London, UK
Format: Fireside Chat
Date and Time: Wednesday, November 15, 2:30-2:55 PM GMT
Webcast: https://wsw.com/webcast/jeff287/eras

6^th Annual Evercore ISI HealthCONx Conference (November 28 – 30, 2023)
Location: Kimpton Epic Hotel, Miami, FL
Format: Fireside Chat
Date and Time: Tuesday, November 28, 11:15-11:35 AM ET
Webcast: https://wsw.com/webcast/evercore39/eras

An archived replay of the events will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.

FAQ

What conferences will Erasca, Inc. participate in November 2023?

Erasca, Inc. (Nasdaq: ERAS) will participate in Jefferies London Healthcare Conference and 6th Annual Evercore ISI HealthCONx Conference.

What is the focus of Erasca, Inc.?

Erasca, Inc. is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancer.

Where can I find the webcasts of the events?

The webcasts will be available at https://wsw.com/webcast/jeff287/eras and https://wsw.com/webcast/evercore39/eras.

Will there be archived replays of the events?

Yes, archived replays will be available for 30 days following the webcast at Erasca.com/events.